What is the out-of-pocket price of Lynparza/Olaparib tablets in 2026?

Olaparib is a targeted drug used to treat certain types of cancer, especially for patients with ovarian cancer and breast cancer with BRCA gene mutations. It is a PARP inhibitor that enhances the death of tumor cells by blocking the ability of cancer cells to repair their DNA. This drug has already achieved clinical use in the international market and has been approved by regulatory agencies in multiple countries for the treatment of various cancers.

In China, the original drug of Lynparza has been officially launched and has been included in medical insurance (Class B medical insurance), but it needs to meet certain indication conditions. Specifically, the use of Lynparza in China is mainly targeted at patients with BRCA gene mutations, especially those with ovarian cancer and breast cancer who have experienced chemotherapy but whose disease still progresses. The pharmaceutical specifications of Lynparib are usually 100 mg, 7 tablets, and 8 tablets, and 150 mg, 56 tablets. Patients purchase it according to the doctor's prescription.

As for price, the cost of Lynparza may fluctuate depending on different regions, medical insurance reimbursement status, and hospitals. In2026, the medical insurance price of Lynparza is expected to still be around four to five thousand yuan. The specific price is also affected by various factors such as medical insurance reimbursement ratio, drug supply, and market competition. For patients without medical insurance reimbursement, the out-of-pocket price of Lynparza will be relatively high. Especially for those patients who cannot obtain payment support through medical insurance, the financial burden of the drug may be heavy.

For Medicare patients, the cost of the drug is usually reduced. When purchasing Lynparza, patients should first consult the local hospital pharmacy about the specific process and ratio of medical insurance reimbursement. As olaparib is an important drug in cancer treatment, its price remains a focus for many patients. As the needs of more cancer patients grow, more medical insurance policies and drug price optimization measures may be introduced in the future to reduce the financial burden on patients.

Keyword tags: Olaparib,Olaparib, medical insurance price, BRCA gene, PARP inhibitor, cancer treatment, drug price, medical insurance reimbursement, ovarian cancer, breast cancer

Reference materials:https://en.wikipedia.org/wiki/Olaparib